Samsung Life Science Fund

The Samsung Life Science Fund is a corporate venture capital fund established through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures. The fund focuses on investing in advanced biopharmaceutical technologies, including gene therapies and antibody-drug conjugates (ADCs), aiming to bring meaningful impact to patients worldwide. It seeks to foster the growth of next-generation technologies by supporting innovative biotech companies with promising technologies.

The fund's investment strategy includes targeting early-stage companies specializing in gene therapies, ADCs, and other advanced biopharmaceutical technologies. It has made investments in various biotech firms, such as Araris Biotech AG, AimedBio, Generate: Biomedicines, BrickBio, and Arbor Biotechnologies, reflecting its commitment to advancing innovation in the biopharmaceutical sector. The fund's geographical focus spans South Korea, the United States, Switzerland, and the United Kingdom, aligning with its global investment approach.

Through these strategic investments, the Samsung Life Science Fund aims to build technological competitiveness in the bio-healthcare industry and contribute to improving the quality of life for patients worldwide. By collaborating with innovative biotech companies, the fund seeks to accelerate the development of next-generation biopharmaceutical technologies and address unmet medical needs across various therapeutic areas.